Press Releases April 20, 2026 04:09 PM

SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026

SI-BONE Announces Q1 2026 Financial Results Release and Conference Call on May 11, 2026

By Hana Yamamoto SIBN
SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
SIBN

SI-BONE, Inc., a Nasdaq-listed company specializing in procedural solutions for compromised bone health, announced it will report its first quarter 2026 financial results on May 11, 2026, after market close. Management will hold a conference call to discuss the results, with live webcast access for investors. The company continues to lead in biomechanical innovations targeting spinopelvic anatomy and has performed over 140,000 clinical procedures since 2009, supported by extensive clinical evidence.

Key Points

  • SI-BONE will report Q1 2026 financial results on May 11, 2026, followed by a management conference call.
  • The company specializes in procedural solutions addressing clinical challenges related to compromised bone, particularly in spinopelvic anatomy.
  • SI-BONE has a strong clinical foundation with over 140,000 procedures performed and multiple clinical trials supporting its technologies, impacting the medical devices and healthcare sectors.

SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the first quarter of 2026 after market close on Monday, May 11, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/vde24u4q. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 180 peer reviewed publications.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved


Risks

  • Financial performance for Q1 2026 is unknown and could deviate from expectations, introducing stock volatility, relevant to investors in medical devices.
  • Market adoption and competitive dynamics in the healthcare and orthopedic sectors may affect future revenues and growth potential.
  • Regulatory and clinical trial outcomes could impact the company’s ability to develop and commercialize new procedural technologies, influencing the medical technology sector.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026